

## // TREATMENTS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)

Ref-Nr: TA-P-1305

### HINTERGRUND

Changes in lifestyle over the last few decades such as high caloric intake (e.g. through high-fat, high-fructose and high-glucose diets) combined with a sedentary lifestyle have increased the incidence of overweight and metabolic syndrome, which is characterized by abdominal obesity, insulin resistance, hypertonia and dyslipidemia. The latest WHO cancer report predicts a doubling in cancer incidence within the next two decades, the great majority of which will be attributable to modifiable risk factors such as high caloric intake, smoking and a sedentary lifestyle. The liver, which is the most important metabolic organ in the body, is greatly affected by a chronic state of hypercaloric uptake, overweight, sedentary lifestyle and the resulting pathology (metabolic syndrome). Non-alcoholic fatty liver disease (NAFLD), comprising several liver diseases including NAFL and NASH, which is the most frequent liver disease world-wide, is a clinical manifestation of overweight and metabolic syndrome. The prevalence of NAFL is increasing globally. Currently, 90 million Americans and 40 million Europeans suffer from NAFLD. A significant number of NAFL patients develop non-alcoholic steatohepatitis (NASH), fibrosis and, subsequently, hepatocellular carcinoma (HCC).

### LÖSUNG

Compounds were identified that target thrombocyte activity or aggregation capacity through cellular components for the treatment of diseases associated with non-alcoholic fatty liver disease (NAFLD). These compounds are effective for treating non-alcoholic steatohepatitis (NASH), an advanced stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and hepatocellular carcinoma (HCC). Also provided are methods for screening for new NASH therapeutics.

### VORTEILE

Treatment of non-alcoholic steatohepatitis (NASH), an advanced stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and hepatocellular carcinoma (HCC).



Deutsches  
Krebsforschungszentrum DKFZ

Dr. Dirk Kuck  
06221-42-2945  
d.kuck@dkfz.de  
www.dkfz.de

### ENTWICKLUNGSSTAND

Prälinik

### CATEGORIES

//Therapie und Wirkstoffe //Medizin  
und Pharma

ANWENDUNGSBEREICHE

Pharmaceutical composition

---